Holen Sie sich die Stockscreener-App
10.76
2.45%
-0.27
Vorhandelsmarkt:
10.61
-0.15
-1.39%
Schlusskurs vom Vortag:
$11.03
Offen:
$10.99
24-Stunden-Volumen:
292.16K
Relative Volume:
0.63
Marktkapitalisierung:
$667.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-41.43M
KGV:
-13.62
EPS:
-0.79
Netto-Cashflow:
$-39.97M
1W Leistung:
-14.13%
1M Leistung:
+6.22%
6M Leistung:
+67.86%
1J Leistung:
-2.89%
1-Tages-Spanne:
$10.40
$11.06
1-Wochen-Bereich:
$10.40
$13.21
52-Wochen-Spanne:
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Vergleichen Sie GHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
10.76 | 667.42M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2025-03-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-02-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-08-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-16 | Eingeleitet | ROTH Capital | Buy |
Gh Research Plc Aktie (GHRS) Neueste Nachrichten
(GHRS) Proactive Strategies - news.stocktradersdaily.com
How To Trade (GHRS) - news.stocktradersdaily.com
Guggenheim starts GH Research at Buy, sees long-term upside potential - Yahoo Finance
Guggenheim Initiates Coverage of GH Research (GHRS) with Buy Recommendation - Nasdaq
GH Research PLC (GHRS) Shares Rise Despite Market Challenges - The News Heater
How to Take Advantage of moves in (GHRS) - news.stocktradersdaily.com
GH Research (NASDAQ:GHRS) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
GH Research PLC (NASDAQ:GHRS) Receives $30.67 Consensus PT from Brokerages - Defense World
Q1 Earnings Forecast for GH Research Issued By HC Wainwright - Defense World
RBC Capital Initiates Coverage of GH Research (GHRS) with Outperform Recommendation - Nasdaq
FY2029 EPS Estimates for GH Research Lifted by HC Wainwright - Defense World
GH Research initiated with an Outperform at RBC Capital - TipRanks
GH Research PLC Reports 2024 Financial Results and Clinical Progress - TipRanks
H.C. Wainwright maintains $40 target on GH Research stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $40 target on GH Research stock - Investing.com
Postpartum Depression Pipeline Revealed in 2025 Forecast Report Featuring GH Research, Reunion Neuroscience, Lipocine, and Brii Biosciences - GlobeNewswire Inc.
Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 - MSN
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
GH Research (GHRS) to Release Quarterly Earnings on Thursday - MarketBeat
GH Research (NASDAQ:GHRS) Announces Quarterly Earnings Results - MarketBeat
H.C. Wainwright maintains buy on GH Research stock, $40 target - MSN
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Psychedelic: GH Research, Compass Pathways report earnings results - Yahoo Finance
GH Research (NASDAQ:GHRS) Given New $32.00 Price Target at Stifel Nicolaus - MarketBeat
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Form F-3 GH Research PLC - StreetInsider.com
GH Research Reports 2024 Financial Results and Clinical Progress - TipRanks
Can GH Research's Depression Drug Change Treatment Paradigms? Phase 2b Shows Striking 57.5% Remission Rate - StockTitan
Stifel raises GH Research stock target to $32 on strong trial data - Investing.com
Stifel raises GH Research stock target to $32 on strong trial data By Investing.com - Investing.com South Africa
GH Research PLC (GHRS): Among the Best Performing Small Cap Stocks So Far In 2025 - Insider Monkey
Small-Cap Stocks Surge: GH Research, Society Pass and Reborn Coffee Lead Monday Gainers - HPBL
GHRS Stock Rallies 55% in a Week: Here's What You Should Know - MSN
Cantor Fitzgerald Forecasts GH Research FY2024 Earnings - Defense World
GH Research (NASDAQ:GHRS) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) with Overweight Recommendation - MSN
Cantor Fitzgerald sets GH Research stock Overweight, $14 target By Investing.com - Investing.com Australia
Cantor Fitzgerald sets GH Research stock Overweight, $14 target - MSN
GH Research initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald Initiates GH Research at Overweight -February 13, 2025 at 07:35 am EST - Marketscreener.com
Finanzdaten der Gh Research Plc-Aktie (GHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.89%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):